tbuckley/cabot-search huggingface dataset:
Prevalence of allergic cat and dog sensitization in adult patients with allergic rhinitis from two German Federal States
Authors: G. Balakirski, M. Bas, L. Kaiser, Z. Hajdu, W. Dott, Hans Merk, Stefani Roeseler, H. G. Muecke, J. M. Baron, Martin Leverkus, W. Straff, H. Bier, A. Chaker, S. Gerdsen, K. Czaja, U. Strassen, C. Hoeflich
Journal: Allergy (2016)
Validation of the MESH, HKLC and BCLC classification in a large German cohort of hepatocellular carcinoma patients
Authors: S. Franck, I. Schmidtmann, E. Heil, S. Koch, C. Czauderna, M.-A. Wörns, M. Sprinzl, R. Klöckner, P. Galle, J. Marquardt, A. Weinmann
Journal: Journal of Hepatology (2018)
Transient elastography as a screening method for chronic liver disease in apparently healthy population. Results from de ETHON cohort
Authors: E. Llop, P. Iruzubieta, C. Perelló, J. Cabezas, D. Escudero-García, M. González, M.H. Conde, L. Puchades, M.T.A. Loste, M. Serra, J. Crespo, J.L.C. Panero
Journal: Journal of Hepatology (2018)
Hypomorphic Rag1 mutations alter the preimmune repertoire at early stages of lymphoid development
Authors: L. M. Ott de Bruin, M. Bosticardo, A. Barbieri, S. G. Lin, J. H. Rowe, P. L. Poliani, K. Ching, D. Eriksson, N. Landegren, O. Kämpe, J. P. Manis, L. D. Notarangelo
Journal: Blood (2018)
Occult Hepatitis B infection is frequent and a risk factor of advanced liver disease in The Gambia, West Africa
Authors: G. Ndow, D. Cohen, Y. Shimakawa, M.L. Gore, R. Njie, P. Suso, B. Sanneh, I. Baldeh, M. Mendy, U. D’alessandro, M. Thursz, I. Chemin, M. Lemoine
Journal: Journal of Hepatology (2018)
TCTAP C-201 Very Late Stent Thrombosis Derived from Thin-cap Neoatheroma and Fibroatheroma with Plaque Rupture Assessed by Optical Coherence Tomography
Authors: Yongcheol Kim, Myung-Ho Jeong, Min Chul Kim, Doo Sun Sim, Young Joon Hong, Youngkeun Ahn
Journal: Journal of the American College of Cardiology (2018)
Solving the Shortage of Primary Care Physicians-Reply
Authors: George D. Lundberg
Journal: JAMA (1993)

In Reply.  —Drastic problems require the consideration of drastic solutions; if not sooner, more drastic later. Our imbalance of generalists and specialists has been developing for a long time. The new marketplace will correct it. The move back is just beginning nationally but is already advanced in some American locales. Our oversupply of many specialists and subspecialists will become apparent to nearly all in the very near future. Competent primary care physicians will be in great demand. What will happen to the physicians in the oversupplied specialties? The best ones will remain as specialists and subspecialists; the quick and lucky others will get first in line to retrain to become competent in and practice primary care in the new systems. The slow and the resisters will try to move geographically, buying some time. Early retirement or joblessness will then result for the unfortunate. Resistance will be extreme. Many specialists will
Molecular subtyping of colon cancer (CC) based on mutational status of RAS, BRAF, and DNA mismatch repair (MMR) proteins. Prognostic value.
Authors: Gil Raga Mireia, Sandra Gallach, Eloisa Jantus-Lewintre, Maria Jose Safont, Garcia Martinez Maria Luisa, Javier Garde-Noguera, Ruiz Carmona Maria Dolores, Sara Blasco, Vicent Giner-Bosch, Carlos Camps
Journal: Journal of Clinical Oncology (2016)

e15094 Background: CC is a heterogeneuous disease with clinical, pathological and biological variability. Molecular classification could indentify prognostic subtypes. Methods: 105 patients with stage I-III were included in the study. KRAS, NRAS (Exons 2,3,4) and BRAFV600E mutations were analyzed by a PCR-based assay. MMR (MLH1 and MSH2) proteins expression were analyzed by immunohistochemistry; loss of expression of any indicated deficient (dMMR) vs proficient MMR (pMMR). CC was categorized into 5 subtypes: Traditional (T) (pMMR; wt BRAF and RAS); Alternate (A) (pMMR; wt BRAF and mutant RAS); Serrated (S) (pMMR; mutant BRAF and wt RAS); Serrated dMMR (Sd) (dMMR; mutant BRAF and wt RAS) and Familial (F) (dMMR; wt BRAF, any RAS). Non-parametric tests were used for correlation with clinico-pathological variables and Cox models for association with Disease Free Survival (DFS). Results: Mutational status: 41% KRAS, 5% NRAS and 11% BRAF mutations. MMR status: dMMR 19%; pMMR 81%. Molecular subtypes: T 35%, A 39%, S 7%, Sd 5% and F 14%. Right-sided CC 46%; high grade (HG) CC 12%. Right-sided and dMMR CC showed higher rate of BRAF mutations (21% vs 4% p = .011 and 25% vs 8% p = .034). Stage II and III CC showed higher rate of BRAF mutations vs stage I (14% and 21% vs 0%, respectively; p < .005). dMMR CC was more often right-sided (85% vs 37%, p < .001) and had more HG histology (31% vs 8%, p = .006). T subtype vs others was more likely left-sided (78% vs A 55% vs S 28% vs Sd 0% vs F 20%; p < 0.005). S dMMR and F vs A were more likely right-sided (100% and 80 % vs 45 %; p < .05). F vs T and vs A CC had more HG (33% vs 8%, p = .039; vs 7%, p = .026). Risk of progression is higher in mutated KRAS CC (Odds ratio (OR) 3,36; CI: 1,19-9,47 p = .017). RAS mutated CC showed higher risk of death (OR 5,11; CI: 1,00-25,43 p = .040). Wt KRAS and wt RAS CC showed better DFS (HR 0,31 CI 0.12-0.79 p = .015 and HR 0,39 CI 0,15–1,00 p = .051). T vs S showed better DFS (HR 0,21 IC 0,04 – 0,95 p = .044). S and A together compared to T, showed a tendency to a worse DFS (HR 2,86 IC 0,93–0,78 p = .066). Conclusions: This molecular classification identifies prognostic groups with different clinical and pathological features in early-stage CC.
Abstract 55: Histological And Rheological Evaluation At Coronary Artery Lesions In Patients With Kawasaki Disease Within 2 Years From Onset
Authors: Watanabe Makoto
Journal: Circulation (2015)

Background: Some paper reported that intravascular ultrasound (IVUS)- virtual histology (VH) showed atherogenesis in the evolution of coronary artery lesions (CAL) in young adults long after Kawasaki disease(KD). However, there is no report about those findings during early phase of KD. Purpose: We perform coronary intimal histologic evaluation by IVUS-VH for KD patients with CAL within two years from onset. Furthermore, we calculate shear stress in the target site and examine whether rheological potential affects to vascular histological change after KD. Subjects and Methods: IVUS-VH was performed in 12 Japanese KD patients (median age, 5.1 years) during 2 years after onset of KD (median, 10.2months) . All these patients had giant aneurysm in another branches. We investigated 20 coronary branches including 10 sites of small aneurysm (s-AN), 10 sites of regressed s-AN, and 20 sites of normal segment. Each of the 4 plaque components was assigned a respective color and defined as follows: fibrous area (green); fibro-fatty area (yellow) ; necrotic core area (red); and dense calcium area (white). Moreover, we measured average coronary peak flow velocity by Flow wire and calculated shear stress in the each sites. Results: 10 sites of s-AN showed prominent endothelial hypertrophy with fibrous and/or fibro-fatty plaques. In 7 sites of these 10 sites, dense calcium and necrotic core localized which indicates early phase of atherosclerosis. 10 sites of regressed s-AN had circumferential endothelial hypertrophy occupying mainly fibrous and/or fibro-fatty plaques composition. In 8 sites of these regressed 10 sites, dense calcium and necrotic core locally existed. On the other hand, normal segment in 20 sites had no plaque in 19 sites and trivial plaque in 1 site. Moreover, shear stress in all evaluated VH sites were within normal limit, which shows rheological potential doesn’t affect to vascular remodeling in such coronary artery lesions. Conclusions: IVUS-VH study revealed that initial atherosclerotic findings locally existed not only at small aneurysm site but also at regressed site. Therefore, careful further investigation to vascular remodeling in KD patients with CAL including regressed s-AN will be need.
Preparation, characterization and in vivo evaluation of alginate-coated chitosan and trimethylchitosan nanoparticles loaded with PR8 influenza virus for nasal immunization
Authors: Jafar Mosafer, Amir-Hossein Sabbaghi, Ali Badiee, Solmaz Dehghan, Mohsen Tafaghodi
Journal: Asian Journal of Pharmaceutical Sciences (2018)

For efficient mucosal vaccine delivery, nanoparticulate antigens are better taken by microfold cells in the nasal associated lymphoid tissue and also dendritic cells. Nanoparticles based on polymers such as chitosan (CHT) and its water soluble derivative, trimethylchitosan (TMC), could be successfully used as carrier/adjuvant for this purpose. Sodium alginate, a negatively charged biopolymer, could modify the immunostimulatory properties of CHT and TMC NPs and increase their stability. Sodium alginate (ALG)-coated chitosan (CHT) and trimethylchitosan (TMC) nanoparticles (NPs) loaded with inactivated PR8 influenza virus were successfully prepared by direct coating of the virus with CHT or TMC polymers to evaluate their immunoadjuvant potential after nasal immunization. After nasal immunizations in BALB/c mice, PR8-CHT formulation elicited higher IgG2a and IgG1 antibody titers compared with PR8-TMC. ALG coating of this formulation (PR8-CHT-ALG) significantly decreased the antibody titers and a less immune response was induced than PR8-TMC-ALG formulation. PR8-TMC-ALG formulation showed significantly higher IgG2a/IgG1 ratio, as criteria for Th1-type immune response, compared with PR8-CHT-ALG and PR8 virus alone. Altogether, the PR8-TMC-ALG formulation could be considered as an efficient intranasal antigen delivery system for nasal vaccines.
TCTAP A-161 Impact of Renal Function on Stroke or Systemic Embolism Following Transcatheter Aortic Valve Replacement
Authors: Ungjeong Do, Tae-Oh Kim, Sangwoo Park, Sun Hack Lee, Yong-Hoon Yoon, Sang Yong Om, Minsoo Kim, Hanbit Park, Sang-Cheol Cho, Kyusup Lee, Osung Kwon, Do-Yoon Kang, Euihong Ko, Pil Hyung Lee, Jung-Min Ahn, Duk-Woo Park, Seung-Whan Lee, Young-Hak Kim, Seong-Wook Park, Seung-Jung Park
Journal: Journal of the American College of Cardiology (2018)
Trustworthiness in Untrustworthy Times: Response to Open Peer Commentaries on <i>Beyond Consent</i>
Authors: Stephanie A. Kraft, Mildred K. Cho, Katherine Gillespie, Nina Varsava, Kelly E. Ormond, Benjamin S. Wilfond, Sandra Soo-Jin Lee
Journal: The American Journal of Bioethics (2018)

This article refers to:Beyond Consent: Building Trusting Relationships With Diverse Populations in Precision Medicine Research
Diagnostic accuracy of point-of-care natriuretic peptide testing for chronic heart failure in ambulatory care: systematic review and meta-analysis
Authors: Kathryn S Taylor, Jan Y Verbakel, Benjamin G Feakins, Christopher P Price, Rafael Perera, Clare Bankhead, Annette Plüddemann
Journal: BMJ (2018)

<h3>Abstract</h3> <h3>Objective</h3> To assess the diagnostic accuracy of point-of-care natriuretic peptide tests in patients with chronic heart failure, with a focus on the ambulatory care setting. <h3>Design</h3> Systematic review and meta-analysis. <h3>Data sources</h3> Ovid Medline, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, Database of Abstracts of Reviews of Effects, Embase, Health Technology Assessment Database, Science Citation Index, and Conference Proceedings Citation Index until 31 March 2017. <h3>Study selection</h3> Eligible studies evaluated point-of-care natriuretic peptide testing (B-type natriuretic peptide (BNP) or N terminal fragment pro B-type natriuretic peptide (NTproBNP)) against any relevant reference standard, including echocardiography, clinical examination, or combinations of these, in humans. Studies were excluded if reported data were insufficient to construct 2×2 tables. No language restrictions were applied. <h3>Results</h3> 42 publications of 39 individual studies met the inclusion criteria and 40 publications of 37 studies were included in the analysis. Of the 37 studies, 30 evaluated BNP point-of-care testing and seven evaluated NTproBNP testing. 15 studies were done in ambulatory care settings in populations with a low prevalence of chronic heart failure. Five studies were done in primary care. At thresholds &gt;100 pg/mL, the sensitivity of BNP, measured with the point-of-care index device Triage, was generally high and was 0.95 (95% confidence interval 0.90 to 0.98) at 100 pg/mL. At thresholds &lt;100 pg/mL, sensitivity ranged from 0.46 to 0.97 and specificity from 0.31 to 0.98. Primary care studies that used NTproBNP testing reported a sensitivity of 0.99 (0.57 to 1.00) and specificity of 0.60 (0.44 to 0.74) at 135 pg/mL. No statistically significant difference in diagnostic accuracy was found between point-of-care BNP and NTproBNP tests. <h3>Conclusions</h3> Given the lack of studies in primary care, the paucity of NTproBNP data, and potential methodological limitations in these studies, large scale trials in primary care are needed to assess the role of point-of-care natriuretic peptide testing and clarify appropriate thresholds to improve care of patients with suspected or chronic heart failure.
Effect of vardenafil on portal hemodynamics in patients with mild and moderate liver dysfunction: a randomized, placebo-controlled trial
Authors: R. Paternostro, B. Heinisch, R. Schwarzer, T. Reiberger, M. Wewalka, P. Schwabl, M. Ferlitsch, M. Mandorfer, M. Peck-Radosavljevic, M. Trauner, A. Ferlitsch
Journal: Journal of Hepatology (2018)
Circulating tumour cell increase as a biomarker of disease progression in metastatic castration-resistant prostate cancer patients with low baseline CTC counts
Authors: D. Lorente, D. Olmos, J. Mateo, D. Dolling, D. Bianchini, G. Seed, P. Flohr, M. Crespo, I. Figueiredo, S. Miranda, H.I. Scher, L.W.M.M. Terstappen, J.S. de Bono
Journal: Annals of Oncology (2018)

BackgroundThe development of treatment response and surrogate biomarkers for advanced prostate cancer care is an unmet clinical need. Patients with baseline circulating tumour cell (BLCTCs) counts <5/7.5 mL represent a good prognosis subgroup but are non-evaluable for response assessment (decrease in CTCs). The aim of the study is to determine the value of any increase in CTCs (CTC progression) as an indicator of progression in prostate cancer patients with low pre-treatment CTCs (<5).Patients and methodsWe carried out a post hoc analysis of patients with BLCTCs < 5 treated in the COU-AA-301 (abiraterone or placebo + prednisone) and IMMC-38 (chemotherapy) trials. The association of CTC progression (increase in CTCs at 4, 8 or 12 weeks) with overall survival (OS) was evaluated in multi-variable Cox regression models. Performance of survival models with and without CTC progression was evaluated by calculating ROC curve area under the curves (AUCs) and weighted c-indices.ResultsOverall, 511 patients with CTCs < 5 (421 in COU-AA-301 and 90 in IMMC-38) were selected; 212 (41.7%) had CTC progression at 4, 8 or 12 weeks after treatment initiation. CTC progression was associated with significantly worse OS [27.1 versus 15.1 m; hazard ratio (HR) 3.4 (95% confidence interval [CI] 2.5–4.5; P < 0.001)], independent of baseline CTCs and established clinical variables. Adding CTC progression to the OS model significantly improved ROC AUC (0.77 versus 0.66; P < 0.001). Models including CTC progression had superior ROC AUC (0.77 versus 0.69; P < 0.001) and weighted c-index [0.750 versus 0.705; delta c-index: 0.045 (95% CI 0.019–0.071)] values than those including CTC conversion (increase to CTCs ≥ 5). In COU-AA-301, the impact of CTC progression was independent of treatment arm.ConclusionsIncreasing CTCs during the first 12 weeks of treatment are independently associated with worse OS from advanced prostate cancer in patients with baseline CTCs < 5 treated with abiraterone or chemotherapy and improve models with established prognostic variables. These findings must be prospectively validated.
Prostate Cancer Screening—A New Recommendation for Meaningful Physician-Patient Conversations
Authors: Anita D. Misra-Hebert, Michael W. Kattan
Journal: JAMA Oncology (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Abstract 19820: The Threshold for Left Ventricular Ejection Fraction and Risk of Mortality or Cardiac Transplant in Cardiac Sarcoidosis is Higher Than Traditional Heart Failure Cohorts
Authors: David G Rosenthal, Kristen K Patton, Bradley J Petek, Daniel M Arnett, Logan Vincent, Paco E Bravo, Ganesh Raghu, Carolina S Masri, Richard K Cheng
Journal: Circulation (2017)

Introduction:  Left ventricular systolic dysfunction (LVD) occurs in progressive cardiac sarcoidosis (CS) and is associated with increased cardiovascular morbidity and mortality. Due to the unpredictable course of CS, the degree of LVD required to substantially increase the risk of death or transplant remains incompletely understood. We sought to establish this threshold and hypothesized that a lesser degree of LVD in CS patients compared to other heart failure (HF) cohorts would be associated with increased risk of death or transplant.   Methods:  We identified consecutive patients with CS diagnosed per HRS guidelines or suspected isolated CS. LVEF was examined as a continuous variable and also in a priori defined groups of LVEF ≥ 40% and LVEF    Results:  In 110 patients with CS, LVEF    Conclusion:  Similar to other HF cohorts, decreased LV systolic function in CS is associated with an increased risk of transplant or death. This risk appears to manifest at a higher LVEF threshold (40.4%) than expected in other HF cohorts, highlighting the need for additional risk stratification beyond LVEF in CS patients.
Abstract 2875: Alterations in Beta-catenin, a Constitution of Adhesion Junctions Precede the Gap Junction Connexin43 Remodeling During the Development of Heart Failure
Authors: Masaaki Yoshida, Tomoko Ohkusa, Takashi Sato, Sinsuke Suzuki, Genzou Takemura, Itsuo Kodama, Masunori Matsuzaki
Journal: Circulation (2009)

The intercalated disc contains different junctional complexes (adhesion junctions and gap junctions) that enable the myocardium to function as a syncytium. The adhesion junctions are organized to m...
TCTAP A-019 Early Outcomes in Patients Presenting for Acute ST-elevation Myocardial Infarction and Managed by Prehospital Thrombolysis: Results from a Tunisian Single Center Registry
Authors: Walid Jomaa, Zouhair Jnifene, Ikram Chamtouri, Aymen El Hraiech, Khaldoun Ben Hamda, Faouzi Maatouk
Journal: Journal of the American College of Cardiology (2018)
Effect of high-frequency loading and parathyroid hormone administration on peri-implant bone healing and osseointegration
Authors: Aya Shibamoto, Toru Ogawa, Joke Duyck, Katleen Vandamme, Ignace Naert, Keiichi Sasaki
Journal: International Journal of Oral Science (2018)

The objective of this study is to examine the effect of low-magnitude, high-frequency (LMHF) loading, and anti-osteoporosis medications such as parathyroid hormone (PTH) and bisphosphonates on peri-implant bone healing in an osteoporosis model, and to assess their combined effects on these processes. Thirteen-week-old ovariectomized rats (n = 44) were divided into three groups: PTH, alendronate, and saline. After 3 weeks of drug administration, titanium implants were inserted into the tibiae. Each group was subdivided into two groups: with or without LMHF loading via whole-body vibration (50 Hz at 0.5 g, 15 min per day, 5 days per week). Rats were killed 4 weeks following implantation. Removal torque test, micro-CT analyses (relative gray (RG) value, water = 0, and implant = 100), and histomorphometric analyses (bone-to-implant contact (BIC) and peri-implant bone formation (bone volume/tissue volume (BV/TV))) were performed. Removal torque values and BIC were significantly differed by loading and drug administration (ANOVA). Post hoc analysis showed that PTH-treated groups were significantly higher than the other drug-treated groups. BV/TV was significantly enhanced by PTH administration. In cortical bone, RG values were significantly increased by loading. In trabecular bone, however, RG values were significantly increased by PTH administration. These findings suggest that LMHF loading and PTH can act locally and additively on the bone healing process, improving the condition of implant osseointegration.
Platelet activation, as measured by plasma soluble glycoprotein VI, is not associated with disease activity or ischaemic events in giant cell arteritis
Authors: Richard Conway, Anne Madigan, Niamh Redmond, Laura Helbert, Eamonn S Molloy, Eimear Dunne, Dermot Kenny, Geraldine McCarthy
Journal: Annals of the Rheumatic Diseases (2018)

Giant cell arteritis (GCA) is associated with cranial ischaemic complications (CIC) including vision loss and stroke.1 British Society of Rheumatology and European League against Rheumatism guidelines recommend platelet inhibition with aspirin for most patients with GCA; on the basis of two retrospective studies showing a reduction in CICs, these results were not replicated in two other retrospective studies.2 3 There are no data from prospective or randomised controlled trials to support aspirin use in GCA.4 The glycoprotein VI (GPVI) receptor is found exclusively on platelets and megakaryocytes.5 GPVI is proteolytically cleaved following platelet activation and is detectable in plasma as soluble GPVI (sGPVI).6 Elevated plasma sGPVI signifies platelet activation and an increased risk of cardiovascular events.7 We have recently demonstrated enhanced platelet reactivity as measured by sGPVI in gout and rheumatoid arthritis, …